THERAPY DOSSIER · th-dce65e46d7f1

FTGN, a synthetic tetrapeptide isolated from the spleen of the Middle Asian tortoise Testudo horsfieldii

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Radiation
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 31313444 ↗2019Reported benefit

A peptide from Testudo horsfieldii tortoise spleen as a potential helper for reducing acute radiation syndrome.

MouseRadiationDescribed as active at very low concentrations; exact dose…

Model: Acute radiation syndrome induced by lethal doses of whole-body irradiation, with survival assessed at 30 days

Crude tortoise spleen extract significantly increased survival of mice given lethal irradiation, and iterative chromatographic purification with bioassay screening identified the tetrapeptide FTGN as the active component. FTGN accelerated repopulation of irradiated bone marrow at very low concentra…

Extraction: extract · Supplied extraction confidence: 0.55. Machine-extracted fields require source verification.

Loading the evidence…